OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Neuropathic Corneal Pain
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic Conjunctivitis 
    • NCP Expanded Access
  • Technology
    • Chemerin Receptor
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
    • FAQs
  • News
    • Press releases
    • Media
  • Contact
  • Linkedin
  • Twitter
Select Page
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board

OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board

by Paul | 31st January 2024 | News

London and New York, NY, January 31, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic...

Recent Posts

  • OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
  • OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
  • OKYO Pharma Announces Chairman and Founder Acquires Shares
  • OKYO Pharma Announces Director Acquires Shares
  • OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Technology
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023